arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zymeworks Inc.

ZYME
$28.74 ▼ -2.20 (-7.11%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zymeworks Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B
Dividend Yield —
Revenue Growth -90.6% →
Op. Margin None
ROIC -52.2% ↘
FCF / Share $-0.44 ↗
Trailing P/E —
Price / Book 25.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.59M
↓ -90.6% —
Net Income Profit after all expenses
$-44.16M
↓ -95.1% —
Operating Margin Operating profit as % of sales
-80.1%
↓ -5688.4% 3th
FCF / Share Free cash flow per share
$-0.44
↑ +28.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
4
Returns ↑
23
Cash Quality ↓
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 24 quarters